Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific immunotherapy (AIT) is a therapeutic approach that aims to modify the immune system's response to specific allergens, leading to reduced allergic symptoms and disease progression. It involves the controlled administration of increasing doses of allergens to induce tolerance through various mechanisms including early desensitization of mast cells and basophils, induction of regulatory T cells (Tregs), and a shift in B cell responses from IgE to IgG4 production.
Repeated administration of specific allergens to induce immune tolerance through various mechanisms including mast cell desensitization, induction of Tregs, and alteration of B cell responses (IgE to IgG4 switch).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune System (Immunomodulation via Allergen-Specific Desensitization) (AIT).